All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
High iron levels are a known complicator of survival and overall quality of life for patients with PV. On September 20, 2023, the United States Food and Drug Administration granted fast-track designation to MWTX-003, an investigational anti-transmembrane serine protease 6 (TMPRSS6) monoclonal antibody designed to increase hepcidin levels and, thereby, reduce serum iron levels in patients with polycythemia vera (PV).
Preclinical data have highlighted strong pharmacodynamic effects, with a single dose resulting in a 70% reduction in serum iron levels for 21 days. Moreover, a related β-thalassemia clinical model demonstrated a 4-fold increase in hepcidin levels, a 60–65% reduction in serum and liver iron, increased red blood cell production, and a decrease in spleen weight. A phase I proof-of-mechanism trial is to begin in the second half of 2023. Further plans for a phase 1b/2a proof-of-concept study evaluating the safety and pharmacokinetic profile of MWTX-003 in patients with PV are also in place.
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox